KR20230061473A - 니트로화된 실로시빈 유도체 및 5-ht2a 수용체를 조절하고 정신 장애를 치료하기 위한 이의 용도 - Google Patents

니트로화된 실로시빈 유도체 및 5-ht2a 수용체를 조절하고 정신 장애를 치료하기 위한 이의 용도 Download PDF

Info

Publication number
KR20230061473A
KR20230061473A KR1020237011175A KR20237011175A KR20230061473A KR 20230061473 A KR20230061473 A KR 20230061473A KR 1020237011175 A KR1020237011175 A KR 1020237011175A KR 20237011175 A KR20237011175 A KR 20237011175A KR 20230061473 A KR20230061473 A KR 20230061473A
Authority
KR
South Korea
Prior art keywords
group
alkyl group
alkyl
hydrogen atom
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237011175A
Other languages
English (en)
Korean (ko)
Inventor
질리언 엠. 헤이글
피터 제이. 파키니
장-춘 링
Original Assignee
인베릭 바이오사이언시스 캐나다 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인베릭 바이오사이언시스 캐나다 인크. filed Critical 인베릭 바이오사이언시스 캐나다 인크.
Publication of KR20230061473A publication Critical patent/KR20230061473A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01005—Arylamine N-acetyltransferase (2.3.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/0102—Tryptophan synthase (4.2.1.20)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237011175A 2020-09-02 2021-09-02 니트로화된 실로시빈 유도체 및 5-ht2a 수용체를 조절하고 정신 장애를 치료하기 위한 이의 용도 Withdrawn KR20230061473A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073534P 2020-09-02 2020-09-02
US63/073,534 2020-09-02
PCT/CA2021/051214 WO2022047583A1 (en) 2020-09-02 2021-09-02 Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder

Publications (1)

Publication Number Publication Date
KR20230061473A true KR20230061473A (ko) 2023-05-08

Family

ID=80492288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011175A Withdrawn KR20230061473A (ko) 2020-09-02 2021-09-02 니트로화된 실로시빈 유도체 및 5-ht2a 수용체를 조절하고 정신 장애를 치료하기 위한 이의 용도

Country Status (10)

Country Link
US (1) US20230040398A1 (https=)
EP (1) EP4208446A4 (https=)
JP (1) JP2023539390A (https=)
KR (1) KR20230061473A (https=)
CN (1) CN116782896A (https=)
AU (1) AU2021336667A1 (https=)
CA (1) CA3191095A1 (https=)
IL (1) IL301028A (https=)
MX (1) MX2023002619A (https=)
WO (1) WO2022047583A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20230157342A (ko) 2021-02-12 2023-11-16 인베릭 바이오사이언시스 캐나다 인크. 다중 치환기 실로시빈 유도체 및 사용 방법
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
AU2023234202A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
AU2023382178A1 (en) * 2022-11-18 2025-06-05 Enveric Biosciences Canada Inc. Substituted n-propylamine fused heterocyclic mescaline derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4425399A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
KR20030046395A (ko) * 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 인돌 유도체를 사용하여 안압을 감소시키는 방법
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
DK1859798T3 (en) * 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
CN103601662B (zh) * 2013-11-21 2016-04-06 深圳市药品检验所 一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用
EP3119406B1 (en) * 2014-03-18 2021-01-20 Carmel-Haifa University Economic Corporation Ltd Methods for improving cognitive function via modulation of quinone reductase 2
US11078467B2 (en) * 2016-10-26 2021-08-03 University Of Florida Research Foundation, Incorporated Highly active self-sufficient nitration biocatalysts
US11261157B2 (en) * 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US10640508B2 (en) * 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers

Also Published As

Publication number Publication date
US20230040398A1 (en) 2023-02-09
CN116782896A (zh) 2023-09-19
WO2022047583A1 (en) 2022-03-10
EP4208446A1 (en) 2023-07-12
IL301028A (en) 2023-05-01
AU2021336667A1 (en) 2023-03-30
EP4208446A4 (en) 2024-10-30
AU2021336667A8 (en) 2023-04-13
CA3191095A1 (en) 2022-03-10
JP2023539390A (ja) 2023-09-13
MX2023002619A (es) 2023-04-10

Similar Documents

Publication Publication Date Title
KR20230061473A (ko) 니트로화된 실로시빈 유도체 및 5-ht2a 수용체를 조절하고 정신 장애를 치료하기 위한 이의 용도
US20250057861A1 (en) Halogenated psilocybin derivatives and methods of using
JP6093310B2 (ja) ボアカンギンからノルイボガインを調製するための方法および組成物
JP6049615B2 (ja) ノリボガイン組成物
US20250100967A1 (en) Hydroxylated psilocybin derivatives and methods of using
US11891360B2 (en) Glycosylated psilocybin derivatives and methods of using
JP7482188B2 (ja) ４’－エチルヌクレオシド類似体の酵素的合成
CN112481233B (zh) 制备胞二磷胆碱用酶制剂以及酶催化制备胞二磷胆碱的方法
JPWO2019208571A1 (ja) アミダイト化合物及び該化合物を用いたポリヌクレオチドの製造方法
US20230250127A1 (en) MODIFIED mRNA 5'-CAP ANALOGS
EP3450428A1 (en) Substituted benzamides and methods of use thereof
WO2022104475A1 (en) Nitrilated psilocybin derivatives and methods of using
AU2022218921A1 (en) Multi-substituent psilocybin derivatives and methods of using
KR20200083515A (ko) 2고리 설폰 및 설폭사이드, 및 이의 사용 방법
CN111849845B (zh) 全细胞催化生产5-氨基戊酸的工程菌及5-氨基戊酸的制备方法
US20260103442A1 (en) Aminated psilocybin derivatives and methods of using
AU2009301797A1 (en) Indazole derivative
CN113613650A (zh) 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂
CN110982800B (zh) 一种磺酰基转移酶、应用及其介导的氮丙啶环生物合成方法
WO2023102659A1 (en) Glycosylated isopropylamine mescaline derivatives and methods of using
WO2023102658A1 (en) Glycosylated mescaline derivatives and methods of using
WO2022255469A1 (ja) ホスホロチオエート及びボラノホスフェートを含むキメラ型核酸オリゴマー、及びその製造方法
Blain et al. Chapter Four: Synthesis and non-enzymatic polymerization of 2о-NH2-TNA
WO2015142346A1 (en) Methods and compositions for preparing and purifying noribogaine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202